A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
At a glance
- Drugs Pazopanib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 10 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.